CN113999228A - 一种他达拉非的合成方法 - Google Patents
一种他达拉非的合成方法 Download PDFInfo
- Publication number
- CN113999228A CN113999228A CN202111314820.4A CN202111314820A CN113999228A CN 113999228 A CN113999228 A CN 113999228A CN 202111314820 A CN202111314820 A CN 202111314820A CN 113999228 A CN113999228 A CN 113999228A
- Authority
- CN
- China
- Prior art keywords
- reaction
- tadalafil
- added
- methyl ester
- ester hydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960000835 tadalafil Drugs 0.000 title claims abstract description 37
- 238000001308 synthesis method Methods 0.000 title claims abstract description 5
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 title claims 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims abstract description 42
- SATCULPHIDQDRE-UHFFFAOYSA-N piperonal Chemical compound O=CC1=CC=C2OCOC2=C1 SATCULPHIDQDRE-UHFFFAOYSA-N 0.000 claims abstract description 34
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims abstract description 24
- XNFNGGQRDXFYMM-UHFFFAOYSA-N hydron;methyl 2-amino-3-(1h-indol-3-yl)propanoate;chloride Chemical compound [Cl-].C1=CC=C2C(CC([NH3+])C(=O)OC)=CNC2=C1 XNFNGGQRDXFYMM-UHFFFAOYSA-N 0.000 claims abstract description 22
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 19
- 229940081310 piperonal Drugs 0.000 claims abstract description 17
- MIOPJNTWMNEORI-XVKPBYJWSA-N (R)-camphorsulfonic acid Chemical compound C1C[C@]2(CS(O)(=O)=O)C(=O)C[C@H]1C2(C)C MIOPJNTWMNEORI-XVKPBYJWSA-N 0.000 claims abstract description 14
- 238000010438 heat treatment Methods 0.000 claims abstract description 9
- 239000002904 solvent Substances 0.000 claims abstract description 9
- 238000006243 chemical reaction Methods 0.000 claims description 71
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 66
- 238000002360 preparation method Methods 0.000 claims description 10
- 108010077895 Sarcosine Proteins 0.000 claims description 7
- VEWCAFQJYMQLJB-UHFFFAOYSA-N 2-[ethyl(methyl)amino]acetic acid;hydrochloride Chemical compound Cl.CCN(C)CC(O)=O VEWCAFQJYMQLJB-UHFFFAOYSA-N 0.000 claims description 2
- FKASAVXZZLJTNX-UHFFFAOYSA-N 2-(dimethylamino)acetic acid;hydrochloride Chemical compound [Cl-].C[NH+](C)CC(O)=O FKASAVXZZLJTNX-UHFFFAOYSA-N 0.000 claims 1
- FOAINFSTWSHMPH-UHFFFAOYSA-N 2-[ethyl(methyl)azaniumyl]acetate Chemical compound CCN(C)CC(O)=O FOAINFSTWSHMPH-UHFFFAOYSA-N 0.000 claims 1
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 claims 1
- WOXKDUGGOYFFRN-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 WOXKDUGGOYFFRN-IIBYNOLFSA-N 0.000 abstract description 38
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 abstract description 8
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 abstract description 6
- 230000001738 genotoxic effect Effects 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 231100000025 genetic toxicology Toxicity 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 4
- 238000004886 process control Methods 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 abstract description 2
- WOXKDUGGOYFFRN-IERDGZPVSA-N cis-tadalafil Chemical compound C1=C2OCOC2=CC([C@H]2C3=C(C4=CC=CC=C4N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 WOXKDUGGOYFFRN-IERDGZPVSA-N 0.000 abstract description 2
- 238000011161 development Methods 0.000 abstract description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 102
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 81
- 239000012074 organic phase Substances 0.000 description 42
- 239000007787 solid Substances 0.000 description 42
- 239000000243 solution Substances 0.000 description 36
- 238000001816 cooling Methods 0.000 description 34
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 27
- 239000011541 reaction mixture Substances 0.000 description 27
- 238000003756 stirring Methods 0.000 description 26
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
- 238000001035 drying Methods 0.000 description 17
- 238000001914 filtration Methods 0.000 description 17
- 238000005406 washing Methods 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 238000002425 crystallisation Methods 0.000 description 10
- 230000008025 crystallization Effects 0.000 description 10
- NIDZUMSLERGAON-UHFFFAOYSA-N ethyl 2-(methylamino)acetate;hydron;chloride Chemical compound Cl.CCOC(=O)CNC NIDZUMSLERGAON-UHFFFAOYSA-N 0.000 description 10
- HQZMRJBVCVYVQA-UHFFFAOYSA-N hydron;methyl 2-(methylamino)acetate;chloride Chemical compound Cl.CNCC(=O)OC HQZMRJBVCVYVQA-UHFFFAOYSA-N 0.000 description 10
- 238000002386 leaching Methods 0.000 description 10
- XNFNGGQRDXFYMM-PPHPATTJSA-N methyl (2s)-2-amino-3-(1h-indol-3-yl)propanoate;hydrochloride Chemical compound Cl.C1=CC=C2C(C[C@H](N)C(=O)OC)=CNC2=C1 XNFNGGQRDXFYMM-PPHPATTJSA-N 0.000 description 10
- 239000008213 purified water Substances 0.000 description 10
- 229910000029 sodium carbonate Inorganic materials 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 239000012065 filter cake Substances 0.000 description 7
- VXGABWCSZZWXPC-UHFFFAOYSA-N methyl 2-(methylamino)acetate Chemical compound CNCC(=O)OC VXGABWCSZZWXPC-UHFFFAOYSA-N 0.000 description 7
- 239000012046 mixed solvent Substances 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- 238000001514 detection method Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 238000007098 aminolysis reaction Methods 0.000 description 3
- BTKSUULMJNNXHG-UHFFFAOYSA-N ethyl 2-(methylamino)acetate Chemical compound CCOC(=O)CNC BTKSUULMJNNXHG-UHFFFAOYSA-N 0.000 description 3
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 229930182827 D-tryptophan Natural products 0.000 description 2
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- KCUNTYMNJVXYKZ-SNVBAGLBSA-N methyl (2r)-2-amino-3-(1h-indol-3-yl)propanoate Chemical compound C1=CC=C2C(C[C@@H](N)C(=O)OC)=CNC2=C1 KCUNTYMNJVXYKZ-SNVBAGLBSA-N 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- -1 for example Chemical compound 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Gynecology & Obstetrics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Indole Compounds (AREA)
Abstract
Description
实施例 | 他达拉非trans异构体(%) |
13 | 0.07 |
14 | 0.05 |
15 | 0.08 |
16 | 0.06 |
17 | 0.05 |
18 | 0.07 |
19 | 0.04 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111314820.4A CN113999228B (zh) | 2021-11-08 | 2021-11-08 | 一种他达拉非的合成方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111314820.4A CN113999228B (zh) | 2021-11-08 | 2021-11-08 | 一种他达拉非的合成方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113999228A true CN113999228A (zh) | 2022-02-01 |
CN113999228B CN113999228B (zh) | 2022-11-04 |
Family
ID=79928080
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111314820.4A Active CN113999228B (zh) | 2021-11-08 | 2021-11-08 | 一种他达拉非的合成方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113999228B (zh) |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1305313A1 (en) * | 2000-08-02 | 2003-05-02 | Lilly Icos LLC | Fused heterocyclic derivatives as phosphodiesterase inhibitors |
WO2004089965A2 (en) * | 2003-04-07 | 2004-10-21 | Cipla Ltd | Topiramate and processes for the preparation thereof |
CN101045740A (zh) * | 2007-04-26 | 2007-10-03 | 杭州盛美医药科技开发有限公司 | 一种托吡酯的制备方法 |
WO2008010231A2 (en) * | 2006-05-26 | 2008-01-24 | Alembic Limited | A process for the purification of topiramate |
CN101979395A (zh) * | 2010-09-17 | 2011-02-23 | 南京理工大学 | 一种托吡酯的制备方法 |
CN102725301A (zh) * | 2010-02-05 | 2012-10-10 | 台湾神隆股份有限公司 | 用于制造和纯化托吡酯的方法 |
CN102725310A (zh) * | 2008-11-25 | 2012-10-10 | 健泰科生物技术公司 | 同等型特异性抗her4抗体 |
CN106397502A (zh) * | 2016-08-31 | 2017-02-15 | 安徽省润生医药股份有限公司 | 一种托吡酯的合成工艺 |
CN110437228A (zh) * | 2019-07-22 | 2019-11-12 | 山东省药学科学院 | 一种他达拉非及其中间体的制备方法 |
CN111253399A (zh) * | 2020-03-30 | 2020-06-09 | 苏州弘森药业股份有限公司 | 一种他达拉非原料药的生产工艺 |
-
2021
- 2021-11-08 CN CN202111314820.4A patent/CN113999228B/zh active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1305313A1 (en) * | 2000-08-02 | 2003-05-02 | Lilly Icos LLC | Fused heterocyclic derivatives as phosphodiesterase inhibitors |
WO2004089965A2 (en) * | 2003-04-07 | 2004-10-21 | Cipla Ltd | Topiramate and processes for the preparation thereof |
WO2008010231A2 (en) * | 2006-05-26 | 2008-01-24 | Alembic Limited | A process for the purification of topiramate |
CN101045740A (zh) * | 2007-04-26 | 2007-10-03 | 杭州盛美医药科技开发有限公司 | 一种托吡酯的制备方法 |
CN102725310A (zh) * | 2008-11-25 | 2012-10-10 | 健泰科生物技术公司 | 同等型特异性抗her4抗体 |
CN102725301A (zh) * | 2010-02-05 | 2012-10-10 | 台湾神隆股份有限公司 | 用于制造和纯化托吡酯的方法 |
CN101979395A (zh) * | 2010-09-17 | 2011-02-23 | 南京理工大学 | 一种托吡酯的制备方法 |
CN106397502A (zh) * | 2016-08-31 | 2017-02-15 | 安徽省润生医药股份有限公司 | 一种托吡酯的合成工艺 |
CN110437228A (zh) * | 2019-07-22 | 2019-11-12 | 山东省药学科学院 | 一种他达拉非及其中间体的制备方法 |
CN111253399A (zh) * | 2020-03-30 | 2020-06-09 | 苏州弘森药业股份有限公司 | 一种他达拉非原料药的生产工艺 |
Non-Patent Citations (1)
Title |
---|
RAVINDRA VEDANTHAM: ""First highly stereocontrolled synthesis of tetrahydro trans- β- carboline derivatives by exploiting the influence of a cyclic amide"", 《ARKIVOC》 * |
Also Published As
Publication number | Publication date |
---|---|
CN113999228B (zh) | 2022-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SU776557A3 (ru) | Способ получени оптически активных антрациклинонов | |
WO2018029711A2 (en) | Process for the preparation of venetoclax | |
Bodanszky et al. | o-Nitrophenyl esters of benzyloxycarbonylamino acids and their application in the synthesis of peptide chains by the in situ technique | |
CN110452283B (zh) | 一种抗肿瘤季铵盐类衍生物及其制备方法及应用 | |
AU2018448845B2 (en) | Method for producing dimethoxybenzene compound | |
CN113999228B (zh) | 一种他达拉非的合成方法 | |
CN112110897B (zh) | 一种氘代克里唑蒂尼及其衍生物的制备方法 | |
CN105849106A (zh) | 阿哌沙班合成中的关键中间体和杂质:阿哌沙班二醇酯 | |
CN113004244A (zh) | 一种曲格列汀杂质及其制备方法和用途 | |
Pál et al. | Synthesis and Complexation Studies of Optically Active Aza-and Diazacrown Ethers Containing a Pyrene Fluorophore Unit | |
CN114773348B (zh) | 一种咪达唑仑的制备方法及其中间体 | |
CN113292629B (zh) | 薯蓣皂苷元羟肟酸类衍生物及其制备方法和应用 | |
JPH09507674A (ja) | 6,9−ビス〔(2−アミノメチル)アミノ〕ベンゾ〔g〕イソキノリン−5,10−ジオン及びそのジマレイン酸塩の改良合成方法 | |
CN110078664B (zh) | 一种光气荧光探针及其制备方法 | |
CN106478506B (zh) | 半水绿卡色林盐酸盐的制备方法 | |
CN116253741B (zh) | 一种贝洛替康衍生物的合成方法 | |
CN109516973A (zh) | 取代嘧啶类化合物、其制备方法及用途 | |
CN112375066B (zh) | 一类含8-(苯甲酰基氨基)喹啉的1,8-萘酐类衍生物及其合成和应用 | |
CN110498796B (zh) | 一种含磺酰氟基团的他达那非类似物及其合成方法 | |
CN113248505B (zh) | 伊曲茶碱去甲基杂质的制备方法 | |
CN109336895B (zh) | 一种福尔可定的合成方法 | |
KR20070014164A (ko) | 5,11-디하이드로-11-에틸-5-메틸-8-{2-{(1-옥시도-4-퀴놀리닐)옥시}에틸}-6H-디피리도[3,2-b:2',3'-e][1,4]디아제핀-6-온의 결정 형태 | |
Patel et al. | Formation, dealkylation, and nucleophilic substitution of some mono-and di-alkoxypyridoazepines | |
CN116854637A (zh) | 三种他达拉非合成工艺副产物及其制备方法 | |
CN116262713A (zh) | 一种二甲磺酸赖右苯丙胺的杂质及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240410 Address after: Room 103, Building 21, Rongchuang Research Center, No. 99 Lize Road, Jiangning District, Nanjing City, Jiangsu Province, 210000 (Jiangning High tech Park) Patentee after: Nanjing Zhuoke Pharmaceutical Technology Co.,Ltd. Country or region after: China Address before: 210009, Ma Jia street, Gulou District, Jiangsu, 26, Nanjing Patentee before: NANJING CHOIPHARM TECHNOLOGY Co.,Ltd. Country or region before: China |